GlassScriptPhysician profile
Edward Curran
NPI 1720041718
$2,177.81
in general payments reported to CMS, 2019-2025
15 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $151 · 2021: $190 · 2022: $409 · 2023: $271 · 2024: $124 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $485.47 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $319.07 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $317.70 | 2025 | Xdemvy |
| Abbvie INC. | $274.64 | 2022-2025 | Durysta, Vuity, Lumigan |
| Alcon Vision LLC | $206.39 | 2019-2025 | Lensx, Tryptyr |
| Shire North American Group INC | $150.21 | 2019 | |
| Bausch & Lomb Americas INC. | $140.28 | 2022-2025 | Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $66.80 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $43.82 | 2019 | |
| Ocular Therapeutix, INC. | $38.10 | 2019-2023 | Dextenza |
| Harrow Eye, LLC | $35.29 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $34.32 | 2024 | Tyrvaya |
| Amgen INC. | $24.46 | 2024 | Tepezza |
| Alimera Sciences, INC. | $21.74 | 2024 | Iluvien, Yutiq |
| Thea Pharma INC. | $19.52 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Curran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.